Lipoxin A augments release of thromboxane from human polymorphonuclear leukocyte suspensions.
Lipoxin A (LXA) is a novel eicosanoid, generated by the interactions of lipoxygenases, which has a variety of biological actions. When added to human polymorphonuclear leukocytes, LXA stimulated thromboxane formation which was monitored as TxB2 by radioimmunoassay. The compound augmented the formation of TxA2 stimulated by the ionophore of divalent cations (A23187). Formation of thromboxane was inhibited by two non-steroidal anti-inflammatory drugs (i.e. indomethacin and proglumetacin). Results of the present study indicate that LXA can provoke the release and transformation of endogenous arachidonic acid to thromboxane. Moreover, they suggest a relationship between lipoxin A and the formation of cyclooxygenase pathway products.
D000001:Calcimycin / Q000494:pharmacology; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000494:pharmacology*; D007210:Indoleacetic Acids / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D044045:Lipoxins; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism*; D013928:Thromboxane A2 / Q000097:blood*; D013929:Thromboxane B2 / Q000097:blood*
D006893:Hydroxyeicosatetraenoic Acids; D007210:Indoleacetic Acids; D044045:Lipoxins; C040527:lipoxin A4; D000001:Calcimycin; D013929:Thromboxane B2; D013928:Thromboxane A2; C019541:proglumetacin; D007213:Indomethacin